http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 17 Sep 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html <p><em>Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures</em></p> <p><em>Chief Technology Officer Amandeep Thind to lead continued innovation</em></p> <p>TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html Thu, 17 Sep 2026 07:00:00 -0400 CNVI CNVIF http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html <p><em>Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures</em></p> <p><em>Chief Technology Officer Amandeep Thind to lead continued innovation</em></p> <p>TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html Thu, 17 Sep 2026 07:00:00 -0400 CNVI CNVIF http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html <p><em>Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures</em></p> <p><em>Chief Technology Officer Amandeep Thind to lead continued innovation</em></p> <p>TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html Thu, 17 Sep 2026 07:00:00 -0400 CNVI CNVIF http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html <p><em>Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures</em></p> <p><em>Chief Technology Officer Amandeep Thind to lead continued innovation</em></p> <p>TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Peer-Reviewed+Case+Report+Highlighting+Clinical+Utility+of+Hybrid+IVUS-OCT+Imaging%2C+and+Provides+Update+on+Management+Team/27072530.html Thu, 17 Sep 2026 07:00:00 -0400 CNVI CNVIF http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178